血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的价值分析

杨青娟

（陕西省澄城县医院，陕西 渭南，715200）

浏览次数：117次 下载次数：400次

摘要：

目的 评价血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的价值。方法 选取在我院接受治疗的终末期糖尿病肾病患者80例作为研究对象，按照随机数字表法将其分为两组（研究组和对照组），每组40例。对照组采取常规血液透析方式进行治疗，研究组则采取血透联合左卡尼汀进行治疗，观察并比较两组患者的胆固醇、血红蛋白、血白蛋白、血肌酐水平和不良反应发生情况。结果 治疗后，两组血红蛋白、血白蛋白、胆固醇和血肌酐水平均优于治疗前，且研究组优于对照组，不良反应发生率低于对照组，差异具有统计学意义（P<0.05）。结论 应用血透联合左卡尼汀法对终末期糖尿病肾病患者进行治疗，能够减少患者营养不良、贫血等情况的发生，且安全性高，具有较高的临床应用价值。

关键词：左卡尼汀；血液透析；终末期糖尿病肾病

中图分类号：R587.2文献标志码：A文章编号：2096-1413(2017)20-0041-02

Value analysis of hemodialysis combined with levocarnitine in patients with end-stage diabetic nephropathy
YANG Qing-juan
(Chengcheng County Hospital of Shaanxi, Weinan 715200, China)

ABSTRACT: Objective To evaluate the treatment value of hemodialysis combined with levocarnitine in patients with end-stage diabetic nephropathy. Methods Eighty cases of patients with end-stage diabetic nephropathy treated in our hospital were included in this study and divided into two groups (study group and control group) according to random number table, with 40 patients in each group. The patients in the control group were treated with routine hematodialysis, while the patients in the study group were treated with hemodialysis combined with levocarnitine. The levels of cholesterol, hemoglobin, blood albumin, serum creatinine and adverse reactions of the two groups were observed and compared. Results After treatment, the levels of hemoglobin, blood albumin, cholesterol and serum creatinine of the two groups were better than those before treatment, and those of the study group were significantly better than the control group, and incidence rate of adverse reaction were significantly lower than those in the control group, the differences between the two groups had statistical significances (P<0.05). Conclusion Hemodialysis combined with levocarnitine in treatment of end-stage diabetic nephropathy may reduce the incidence of malnutrition and anemia, with high safety, which has high clinical application value.

KEYWORDS: levocarnitine; hemodialysis; end-stage diabetic nephropathy

参考文献：
[1] 陈立军.血液透析在终末期糖尿病肾病治疗的研究[J].健康导报: 医学版,2015,5(20):9.
[2] 刁春冬,申玉兰.糖尿病肾病维持血液透析患者联合应用左卡尼汀及促红细胞生成素对肾性贫血的影响[J].中国基层医药,2015,22(10):1561-1564.
[3] 江波,王晓斐,江华,等.联合持续低效缓慢血液透析对终末期糖尿病肾病患者血清癌抗原125、胱抑素C及脑钠肽水平影响[J].临床误诊误治,2016,32(6):49-51.
[4] 秦玉祥,李行勇,刘桂华.左卡尼汀对糖尿病肾病脂代谢的影响[J].中国医学创新,2015,12(4):53-55.
[5] 王红梅.血透联合左卡尼汀法在终末期糖尿病肾病患者治疗中的应用价值[J].糖尿病新世界,2015,18(16):42-44.
[6] 钱春梅,王秦,许涛,等.维持性血透患者应用左卡尼汀治疗的临床分析[J].中国中西医结合肾病杂志,2014,15(10):877-879.
[7] 吴岳春.观察终末期糖尿病肾病患者血透联合左卡尼汀治疗的临床疗效[J].中国民康医学,2015,27(8):62-64.